This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet 2014; 383: 1155-67.ValeyreDPrasseANunesHUzunhanYBrilletPYMüller-QuernheimJ.Sarcoidosis201438311556710.1016/S0140-6736(13)60680-7Search in Google Scholar
Ulaner GA, Lilienstein J, Gönen M, Maragulia J, Moskowitz CH, Zelenetz AD. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. J Clin Oncol 2014; 32: 51-6.UlanerGALiliensteinJGönenMMaraguliaJMoskowitzCHZelenetzAD.False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma20143251610.1200/JCO.2013.50.804424248697Search in Google Scholar
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014; 32: 3048-58.BarringtonSFMikhaeelNGKostakogluLMeignanMHutchingsMMuellerSPet alRole of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group20143230485810.1200/JCO.2013.53.5229501542325113771Search in Google Scholar
Maza S, Buchert R, Brenner W, Munz DL, Thiel E, Korfel A, et al. Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma. Radiol Oncol 2013; 47: 103-10.MazaSBuchertRBrennerWMunzDLThielEKorfelAet alBrain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma2013471031010.2478/raon-2013-0016369108423801905Search in Google Scholar
Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-9.SpaepenKStroobantsSDupontPVan SteenweghenSThomasJVandenberghePet alPrognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?200119414910.1200/JCO.2001.19.2.41411208833Search in Google Scholar
Spagnolo P, Luppi F, Roversi P, Cerri S, Fabbri LM, Richeldi L. Sarcoidosis: challenging diagnostic aspects of an old disease. Am J Med 2012; 125: 118-25.SpagnoloPLuppiFRoversiPCerriSFabbriLMRicheldiL.Sarcoidosis: challenging diagnostic aspects of an old disease20121251182510.1016/j.amjmed.2011.06.00322269612Search in Google Scholar
Brady B, Kamel D, Kiely J, Hennessy B. Dual diagnosis of sarcoidosis and lymphoma. Ir J Med Sci 2013; 182: 283-6.BradyBKamelDKielyJHennessyB.Dual diagnosis of sarcoidosis and lymphoma2013182283610.1007/s11845-012-0854-122983882Search in Google Scholar
Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS. High incidence of falsepositive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20: 309-18.HanHSEscalónMPHsiaoBSerafiniALossosIS.High incidence of falsepositive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens2009203091810.1093/annonc/mdn629273306618842613Search in Google Scholar
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Wholebody positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-33.JerusalemGBeguinYFassotteMFNajjarFPaulusPRigoPet alWholebody positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging1999944293310.1182/blood.V94.2.429Search in Google Scholar
Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 2001; 115: 793-800.NaumannRVaicABeuthien-BaumannBBredowJKroppJKittnerTet alPrognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma200111579380010.1046/j.1365-2141.2001.03147.x11843811Search in Google Scholar
Gawande RS, Khurana A, Messing S, Zhang D, Castaneda RT, Goldsby RE, et al. Differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT. Radiology 2012; 262: 613-22.GawandeRSKhuranaAMessingSZhangDCastanedaRTGoldsbyREet alDifferentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT20122626132210.1148/radiol.1111071522157202Search in Google Scholar
Suen JS, Forse MS, Hyland RH, Chan CK. The malignancy-sarcoidosis syndrome. Chest 1990; 98: 1300-2.SuenJSForseMSHylandRHChanCK.The malignancy-sarcoidosis syndrome1990981300210.1378/chest.98.5.13002225992Search in Google Scholar
Kornacker M, Kraemer A, Leo E, Ho AD. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin’s lymphoma: report of two cases. Ann Hematol 2002; 81: 103-5.KornackerMKraemerALeoEHoAD.Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin’s lymphoma: report of two cases200281103510.1007/s00277-001-0415-611907791Search in Google Scholar
Fishman JA. Approach to the immunocompromised patient with fever and pulmonary infiltrates. In: Marr KA, Thorner AR, editors. Uptodate.com. UpToDate; C 2013 [citated 2014 Oct 19]. Available from: http://www.uptodate.com/FishmanJA.Approach to the immunocompromised patient with fever and pulmonary infiltratesMarrKAThornerARUpToDate; C 2013 [citated 2014 Oct 19]. Available fromhttp://www.uptodate.com/Search in Google Scholar
Brincker H, Wilbek E. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer 1974; 29: 24-52.BrinckerHWilbekE.The incidence of malignant tumours in patients with respiratory sarcoidosis197429245210.1038/bjc.1974.6420090944830144Search in Google Scholar
Brincker H. The sarcoidosis-lymphoma-syndrome. Br J Cancer 1986; 54: 467-73.BrinckerH.The sarcoidosis-lymphoma-syndrome1986544677310.1038/bjc.1986.19920016163756082Search in Google Scholar
Inoue K, Goto R, Shimomura H, Fukuda H. FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. Springerplus 2013; 2: 113.InoueKGotoRShimomuraHFukudaH.FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment2013211310.1186/2193-1801-2-113361002723543853Search in Google Scholar
Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol 2007; 25: 326-33.CohenPRKurzrockR.Sarcoidosis and malignancy2007253263310.1016/j.clindermatol.2007.03.01017560310Search in Google Scholar
Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol 2009; 64: 675-81.ChowdhuryFUSheerinFBradleyKMGleesonFV.Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern2009646758110.1016/j.crad.2009.09.007Search in Google Scholar
Hunsaker AR, Munden RF, Pugatch RD, Mentzer SJ. Sarcoidlike reaction in patients with malignancy. Radiology 1996; 200: 255-61.HunsakerARMundenRFPugatchRDMentzerSJ.Sarcoidlike reaction in patients with malignancy19962002556110.1148/radiology.200.1.86579228657922Search in Google Scholar
Hunt BM, Vallières E, Buduhan G, Aye R, Louie B. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg 2009; 197: 629-32.HuntBMVallièresEBuduhanGAyeRLouieB.Sarcoidosis as a benign cause of lymphadenopathy in cancer patients20091976293210.1016/j.amjsurg.2009.01.00419321155Search in Google Scholar
Brincker H. Sarcoid reactions in malignant tumours. Cancer Treat Rev 1986; 13: 147-56.BrinckerH.Sarcoid reactions in malignant tumours1986131475610.1016/0305-7372(86)90002-2Search in Google Scholar
Haran MZ, Feldberg E, Berrebi A. Lymphoma masking sarcoidosis. Leuk Lymphoma 2002; 43: 1709-10.HaranMZFeldbergEBerrebiA.Lymphoma masking sarcoidosis20024317091010.1080/104281902100000309012400619Search in Google Scholar
Merchant TE, Filippa DA, Yahalom J. Sarcoidosis following chemotherapy for Hodgkin’s disease. Leuk Lymphoma 1994; 13: 339-47.MerchantTEFilippaDAYahalomJ.Sarcoidosis following chemotherapy for Hodgkin’s disease1994133394710.3109/104281994090562997519511Search in Google Scholar
Kim MH, Lee K, Kim KU, Park HK, Lee MK, Suh DS. Sarcoidosis mimicking cancer metastasis following chemotherapy for ovarian cancer. Cancer Res Treat 2013; 45: 354-8.KimMHLeeKKimKUParkHKLeeMKSuhDS.Sarcoidosis mimicking cancer metastasis following chemotherapy for ovarian cancer201345354810.4143/crt.2013.45.4.354389333424454009Search in Google Scholar
Torchio M, Bottaro G, Bertolino G, Comolli G, Bello BD, Invernizzi R, et al. Late-onset sarcoidosis in a patient with gastric mucosa-associated lymphoid tissue non-Hodgkin lymphoma: A case report. Oncol Lett 2014; 8: 1299-301.TorchioMBottaroGBertolinoGComolliGBelloBDInvernizziRet alLate-onset sarcoidosis in a patient with gastric mucosa-associated lymphoid tissue non-Hodgkin lymphoma: A case report20148129930110.3892/ol.2014.2241411462725120711Search in Google Scholar